StreetAlpha.app
Home › Stocks › SER

Serina Therapeutics, Inc. (SER)

$1.12
▼ −6.67%
LAST CLOSE · NOV 20

Serina Therapeutics develops drug candidates using its POZ polymer delivery technology, with a lead treatment for Parkinson's disease. It last closed at $1.12 on Nov 20, down 6.67% on the day. The next earnings report for SER is expected around Wed, Mar 24, 2027, after the close. For the quarter ended Sep 2026, SER reported EPS of -$0.31 on revenue of $125,000. Over its last 8 reports the stock moved an average of 4.7% the session after earnings. Over the last 12 months SER insiders bought $78K of stock on the open market and sold $335K, according to SEC Form 4 filings.

AI Auto Pilots
Is SER in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SER.

Key Stats

Last 12 months
Results
Revenue
$125K
+7.8% vs a year ago
Net income
−$24.5M
−19596.8% margin
EPS (diluted)
−$1.63
Free cash flow
−$22.8M
−18268.8% margin
Valuation
Market cap
$29.8M
26.6M shares
P/E
–
No P/E while losing money
Price to sales
238.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$19.4M
At Sep 30
Shareholder equity
$13.9M
Shares outstanding
26.6M
At Nov 10
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $144K$144KFY2021FY2022: $34K$34KFY2022FY2023: $3.2M$3.2MFY2023FY2024: $56K$56KFY2024FY2025: $130K$130KFY2025

From SER's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 24
Estimated date · After the close
Reported EPS
-$0.31
Quarter ended Sep 2026
Year ago EPS
-$0.45
Same quarter last year
Revenue
$125,000
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.27Dec '24Mar 2025: -$0.49Mar '25Jun 2025: -$0.66Jun '25Sep 2025: -$0.45Sep '25Dec 2025: -$0.31Dec '25Mar 2026: -$0.58Mar '26Jun 2026: -$0.55Jun '26Sep 2026: -$0.31Sep '26Latest -$0.31
Revenue by quarter
Mar 2025: $0Mar '25Jun 2025: $130,000Jun '25Sep 2025: $0Sep '25Dec 2025: $0Dec '25Jun 2026: $0Jun '26Sep 2026: $125,000Sep '26Latest $125,000
How SER moved after its last 8 reports
Average move the session after a report ±4.7%
Nov 12, 2026After the close−1.4%
Aug 13, 2026After the close−1.8%
May 14, 2026After the close−4.7%
Mar 25, 2026After the close−13.9%
Nov 13, 2025Time not announced−2.5%
Aug 11, 2025After the close+7.1%
May 8, 2025After the close−2.0%
Mar 24, 2025After the close−4.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on SERStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on SER
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on SER

Technical Analysis

SER · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 38% below its 20 day and 62% below its 50 day average. It is 77% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 26), oversold. The nearest support is the 52 week low at $1.06, and the nearest resistance the Pivot at $1.15.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 19.3%/day
Key levels
$4.2652 week high+280.4%
$2.09100 day average+86.6%
$1.99Swing high (Jun 5)+77.7%
$1.98200 day average+76.8%
$1.8250 day average+62.5%
$1.5420 day average+37.5%
$1.23Pivot R1+9.8%
$1.15Pivot+2.7%
$1.12Last close
$1.0652 week low−5.4%
$1.03Pivot S1−8.0%
Indicators
RSI (14)26.33Oversold below 30Oversold
MACD-0.17Below its signal lineBearish
Stochastic9.8Near the bottom of its rangeOversold
ADX (14)29.7Trending down
Williams %R-92.4Oversold below −80, overbought above −20Oversold
CCI (20)-148.5Oversold below −100, overbought above 100Oversold
Rate of change−18.8%Change over 10 sessionsBearish
ATR (14)$0.22Typical daily range, 19.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SER

What happened before

See how SER did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow SER usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How SER has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2018.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for SERHow many large options trades hit SER, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

SER Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●9 buying vs 8 selling
  • ▲Held by funds +4.1 pts
  • ▲Funds holding +1
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2827+3.7%
In funds' top 1000–
Held by funds9.4%5.3%+4.1 pts
New / increased4 / 54 / 6−10.0%
Reduced / sold out5 / 34 / 3+14.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SER institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

SER Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$78K5 buys · 4 insiders
Sold$335K17 sales · 1 insider
100% of the selling was under pre-arranged trading plans.
Cluster buy: 3 insiders bought $76K between May 19 and Jun 12.
2025-12 sold $80K2026-01 sold $94K2026-02 sold $20K2026-03 sold $116K2026-05 bought $58K2026-06 bought $18K2026-07 bought $2KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jul 7Stephen K. BrannanDirectorBuy1,000$2.03$2K
Jun 12Karen J WilsonDirectorBuy10,100$1.76$18K
May 22Jay VenkatesanDirectorBuy589$1.78$1K
May 22Karen J WilsonDirectorBuy20,000$1.85$37K
May 19Richard Peter MarshallDirectorBuy12,183$1.65$20K
Mar 23Randall MoreadithChief Scientific OfficerSale plan6,500$2.86$19K
Every insider buy and sale for SER over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See SER insider trades →

From SEC Form 4 filings by SER's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SER is in one of them and how their past SER trades turned out.

SER in the AI portfolios
Loading…

SER News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SER in an article yet. Here's the latest on the wider market.

SER in the news

About Serina Therapeutics

Serina Therapeutics is a biotechnology company based in Huntsville, Alabama. It develops drug candidates that use its proprietary POZ polymer technology, which is designed to control how a drug is released and how long it stays active in the body. Its lead candidate, SER 252, is being developed to treat Parkinson's disease and is in clinical development. The company also plans to work with pharmaceutical partners on other uses of its platform, including RNA-based therapies and antibody drug conjugates.

Headquarters
Huntsville, AL